Where is BBT Biotech headquartered?

XBiotech Germany GmbH is recorded with headquarters in Baesweiler, DE in NovaPharmaNews public regulatory and sponsor datasets.

Is BBT Biotech publicly traded?

Yes — BBT Biotech is listed as a public company with ticker XBIT on NYSE in SEC EDGAR-derived records.

What drugs are associated with BBT Biotech?

We link 1 drug profile(s) where BBT Biotech appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is BBT Biotech sponsoring?

BBT Biotech is linked to 8 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list BBT Biotech as applicant?

31 USPTO PatentsView record(s) name XBiotech Germany GmbH or a normalized variant as applicant.

What pipeline phases does BBT Biotech have in our database?

Phase distribution from linked programs: phase 2: 6, phase 1: 2.

Does BBT Biotech hold EU marketing authorisations in our data?

1 linked drug(s) include EMA EPAR approval metadata.

Where does NovaPharmaNews source data on BBT Biotech?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is BBT Biotech data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is BBT Biotech data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

XBiotech Germany Pharmaceuticals Company Profile

Name: XBiotech Germany intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: Baesweiler, DE
Employees: 30
Programs: 8
Drugs: 6
Patents: 31

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

BBT Biotech is a biotech organization headquartered in Baesweiler, DE. It trades on NYSE under ticker XBIT. Primary therapeutic focus areas include Rheumatoid Arthritis, Pharmacokinetics, Staphylococcus Aureus Bacteremia, Axial Spondyloarthritis, Pancreatic Cancer. NovaPharmaNews links 8 clinical program(s), 1 drug profile(s), and 31 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (6), phase 1 (2).

Company snapshot

BBT Biotech GmbH is your professional and reliable partner in the development, manufacturing and international sales of biopharmaceuticals. BBT Biotech, We are located in Baesweiler near Aachen, Germany, is specialized in the development, manufacturing and international sales of active pharmaceutical ingredients of biological origin. We focus on our two main competences in up- and downstream proce

1 approved product(s) across US/EU regulatory metadata.
8 active pipeline program(s) linked via ClinicalTrials.gov.
31 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for XBiotech Germany. Not investment advice.

Top assets

View drugs (6) View projects (8)

Lead pipeline drugs

anti-
Marketed / approved
folate
Marketed / approved
human igg1 monoclonal antibody specific for human interleukin-1 alpha
Marketed / approved
placebo
Marketed / approved

Active clinical programs

514G3 (2 mg/kg) plus standard IV antibiotic treatment Staphylococcus Aureus Bacteremia
Phase 2
Natrunix Rheumatoid Arthritis
Phase 2
Natrunix 400 mg Rheumatoid Arthritis
Phase 2
Natrunix with MTX placebo (+folate) Rheumatoid Arthritis
Phase 2

Momentum

Proprietary activity score for XBiotech Germany.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 8 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

CNS Pharmaceuticals

TA overlap score 24.2

Recent activity

Latest pipeline, patent, and corporate events for XBiotech Germany.

Jun 5, 2026 Clinical update
XB2001 or Placebo — Phase 2
Jun 5, 2026 Clinical update
Natrunix with MTX placebo (+folate) — Phase 2
Jun 5, 2026 Clinical update
514G3 (2 mg/kg) plus standard IV antibiotic treatment — Phase 2
May 23, 2026 Clinical update
Natrunix — Phase 2
May 23, 2026 Clinical update
Natrunix 400 mg — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is XBiotech Germany?

BBT Biotech is a biotech organization headquartered in Baesweiler, DE. It trades on NYSE under ticker XBIT. Primary therapeutic focus areas include Rheumatoid Arthritis, Pharmacokinetics, Staphylococcus Aureus Bacteremia, Axial Spondyloarthritis, Pancreatic Cancer. NovaPharmaNews
Is XBiotech Germany publicly traded?

Yes. XBiotech Germany is listed with ticker XBIT on NYSE per SEC EDGAR records linked on this profile.
What drugs does XBiotech Germany develop or market?

We link 6 drug profile(s) where XBiotech Germany is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/xbiotech#company-drugs.
What are the latest developments for XBiotech Germany?

In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.
What therapeutic areas does XBiotech Germany focus on?

XBiotech Germany focuses on Rheumatoid Arthritis, Pharmacokinetics, Staphylococcus Aureus Bacteremia based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Immunology

Infectious Disease

Oncology